Nelson Hospital, Nelson Marlborough District Health Board, Nelson, New Zealand.
Department of Ophthalmology, Auckland District Health Board, Auckland, New Zealand; and.
Cornea. 2021 Mar 1;40(3):277-281. doi: 10.1097/ICO.0000000000002619.
To examine the rate and risk factors for band keratopathy after herpes zoster ophthalmicus (HZO) and the outcomes of ethylenediaminetetraacetic acid (EDTA) treatment.
This is a retrospective review of all subjects with HZO seen at Auckland District Health Board between January 2006 and December 2016.
A total of 869 subjects with HZO were included in the study. Median follow-up was 6.3 years (total 5504.4 patient-years). Band keratopathy developed in 13 subjects (1.5%). On multivariate analysis, older age at onset [hazard ratio (HR), 1.092; P = 0.034], intraocular pressure ≥30 mm Hg at presentation (HR, 5.548; P = 0.013), and number of recurrences (HR, 1.849; P < 0.001) were associated with increased risk for band keratopathy. Corneal melt occurred in 22 subjects (2.5%) during the follow-up period. On multivariate analysis, uveitis (HR, 8.618; P = 0.004) and disodium EDTA chelation (HR, 8.666; P < 0.001) were associated with increased risk for corneal melt. EDTA chelation was performed in 8 subjects. Corneal melt occurred after EDTA chelation in 4 subjects, and corneal perforation occurred in 2 subjects. One subject was eviscerated due to severe endophthalmitis after repeated corneal perforation and another required enucleation for recurrent corneal melt and microbial keratitis.
Band keratopathy is an uncommon complication of HZO. Treatment with EDTA chelation might be associated with a significant risk for severe complications in these eyes and should be approached with caution.
研究带状疱疹性眼病(HZO)后带状角膜病变的发生率和危险因素,以及乙二胺四乙酸(EDTA)治疗的结果。
这是对 2006 年 1 月至 2016 年 12 月在奥克兰地区卫生局就诊的所有 HZO 患者进行的回顾性研究。
本研究共纳入 869 例 HZO 患者。中位随访时间为 6.3 年(总随访 5504.4 患者年)。13 例(1.5%)患者发生带状角膜病变。多变量分析显示,发病年龄较大(HR,1.092;P=0.034)、就诊时眼压≥30mmHg(HR,5.548;P=0.013)和复发次数(HR,1.849;P<0.001)与带状角膜病变的风险增加相关。在随访期间,22 例(2.5%)患者发生角膜融解。多变量分析显示,葡萄膜炎(HR,8.618;P=0.004)和二钠 EDTA 螯合(HR,8.666;P<0.001)与角膜融解的风险增加相关。对 8 例患者进行了 EDTA 螯合治疗。EDTA 螯合后 4 例发生角膜融解,2 例发生角膜穿孔。1 例患者因反复角膜穿孔导致严重眼内炎而行眼内容剜除术,另 1 例患者因反复角膜融解和微生物性角膜炎而行眼球摘除术。
带状角膜病变是 HZO 的一种罕见并发症。EDTA 螯合治疗可能与这些眼睛发生严重并发症的风险显著相关,应谨慎使用。